Key facts
- Notable investors include Shanghai Healthcare Capital, Nan Fung Life Sciences.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Editact Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Editact Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Editact Therapeutics
Manufacturer of biopharmaceutical products and biologics development services aims to advance precision medicine and healthcare innovation. The company's offerings feature proprietary biologic drug pipelines, GMP-compliant production capabilities, and integrated R&D workflows, helping hospitals, pharmaceutical developers, and research institutions access safe, effective biologics and therapies, enabling scalable delivery of advanced medical solutions across therapeutic areas.
- Sector
- Healthcare
- HQ
- Hong Kong
- Founded
- 2023
- Ownership
- Privately Held (backing)
Editact Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Editact Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Editact Therapeutics in its N-PORT filings yet. We sweep new filings monthly.